Search results for "HIV"

showing 10 items of 1527 documents

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

2012

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR. © 2012 The Authors. Clinical Microbiol…

AdultMaleMicrobiology (medical)CartDrugmedicine.medical_specialtyGenotypeAnti-HIV Agentsmedia_common.quotation_subjectHuman immunodeficiency virus (HIV)HIV InfectionsDrug resistancemedicine.disease_causeArticleEvolution Molecular03 medical and health sciencesrecent HIV infection0302 clinical medicineInternal medicineDrug Resistance ViralPrevalencemedicineHumansHIV Infection030212 general & internal medicinemedia_common0303 health scienceschronic HIV infection030306 microbiologybusiness.industryAntiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance; Microbiology (medical); Infectious DiseasesAnti-HIV AgentGeneral MedicineMiddle Agedtransmitted resistanceVirologyAntiretroviral therapy3. Good healthAntiretroviral therapyInfectious DiseasesItalyHIV-1Genotypic resistanceFemalebusinessHumanresistance epidemiologyClinical Microbiology and Infection
researchProduct

Identification of Candida dubliniensis among oral yeast isolates from an italian population of human immunodeficiency virus-infected (HIV +) subjects

2002

Candida dubliniensis, an emerging oral pathogen, phenotypically resembles Candida albicans so closely that it is easily misidentified as such. The aim of the present study was to evaluate the usefulness of two phenotypic methods, growth at 45 degrees C and 2,3,5-triphenyltetrazolium chloride (TTC) reduction, for confirming presumptive identification of C. dubliniensis and C. albicans by colony color on CHROMagar Candida (CAC) medium. A combination of these methods was used to establish the prevalence of oral C. dubliniensis in an Italian population of 45 human immunodeficiency virus (HIV)-infected subjects. Twenty-two samples (48.9%) were positive for yeasts on CAC medium producing a total …

AdultMaleMicrobiology (medical)IdentificationSettore MED/07 - Microbiologia E Microbiologia ClinicaAntifungal AgentsImmunologyColony Count MicrobialTetrazolium SaltsHIV InfectionsPolymerase Chain ReactionMicrobiologyCandidiasis OralDrug Resistance FungalSettore MED/28 - Malattie OdontostomatologicheCandida albicansHumansColoring AgentsDNA FungalFluconazoleCandidaMouthTemperatureHIVMiddle AgedCulture MediaOral cavityAgarPhenotypeChromogenic CompoundsItalyCandida dubliniensiDentistry (all)Female
researchProduct

Role of PCR in Diagnosis and Prognosis of Visceral Leishmaniasis in Patients Coinfected with Human Immunodeficiency Virus Type 1

2001

ABSTRACT A group of 76 consecutive human immunodeficiency virus (HIV)-positive patients with fever of unknown origin ( n = 52) or fever associated with pulmonary diseases was evaluated in order to assess the usefulness of PCR with peripheral blood in the diagnosis and follow-up of visceral leishmaniasis. We identified 10 cases of visceral leishmaniasis among the 52 patients with fever of unknown origin. At the time of diagnosis, all were parasitemic by PCR with peripheral blood. During follow-up, a progressive decline in parasitemia was observed under therapy, and all patients became PCR negative after a median of 5 weeks (range, 6 to 21 weeks). However, in eight of nine patients monitored …

AdultMaleMicrobiology (medical)Settore MED/17 - Malattie InfettiveLeishmania donovaniHIV InfectionsParasitemiaPolymerase Chain ReactionImmunopathologymedicineAnimalsHumansLeishmania infantumFever of unknown originbiologyLeishmaniasisDNA ProtozoanMiddle AgedPrognosisvisceral leishmaniasis; HIV; PCR diagnosisSettore MED/07 - Microbiologia e Microbiologia Clinicabiology.organism_classificationmedicine.diseaseVisceral leishmaniasisImmunologyHIV-1Leishmaniasis VisceralFemaleParasitologyViral diseaseLeishmania infantumPolymorphism Restriction Fragment LengthLeishmania donovaniJournal of Clinical Microbiology
researchProduct

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines…

2006

ABSTRACTThis study aimed to determine the effect of highly active anti-retroviral therapy (HAART) and hepatitis C virus (HCV) co-infection on peripheral levels of interleukin (IL)-2, IL-10, IL-12 (p70), IL-18 and soluble tumour necrosis factor receptor type II (sTNFRII). Serum levels were monitored for a 1-year period in 25 patients infected with human immunodeficiency virus-1 (HIV-1) who were naive for HAART at the initiation of the study, and in four HIV-1-infected long-term non-progressors. Serum levels of both IL-18 and sTNFRII at baseline were significantly higher in HIV-1-infected patients than in controls. Baseline levels of IL-18 and sTNFRII were not significantly different in long-…

AdultMaleMicrobiology (medical)hepatitis C virusTime FactorsHAARTHepatitis C virusHepacivirusHIV Infectionsmedicine.disease_causeserum cytokinesReceptors Tumor Necrosis FactorVirusEtanerceptAntiretroviral Therapy Highly ActiveImmunopathologymedicineHumansLongitudinal StudiesDemographybiologyhuman immunodeficiency virusbusiness.industryInterleukinsInterleukinvirus diseasesGeneral MedicineHepatitis Csoluble tumour necrosis factor receptor type IIMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CInfectious DiseasesImmunoglobulin GImmunologyLentivirusHIV-1CytokinesFemaleViral diseasebusinessIL-18Clinical Microbiology and Infection
researchProduct

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial inf…

2008

Background. Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. Methods. The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. Results. The pro…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAnti-HIV AgentsImmunologyantiretroviral therapyMyocardial Infarction610 Medicine & healthHIV Infections2726 Microbiology (medical)Article10234 Clinic for Infectious DiseasesCoronary artery diseasecardiovascular diseaselipidDiabetes mellitusInternal medicinemedicineHumansHIV InfectionMyocardial infarctionAdverse effectHypolipidemic AgentsHypolipidemic Agentbusiness.industryIncidenceIncidence (epidemiology)Anti-HIV AgentHIV2725 Infectious DiseasesMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious DiseasesFemalebusinessBody mass indexDyslipidemiaHuman
researchProduct

Response-adjusted α-interferon therapy for chronic hepatitis C in HIV-infected patients

2000

Abstract In patients with chronic hepatitis C and HIV infection, responsiveness to the standard schedule of α-interferon (IFN) is unsatisfactory. To quantify the effectiveness of tailoring IFN dosage according to HCV viral load under treatment, we enrolled 41 patients (M/F 32/9) chronically coinfected by HCV and HIV with chronic liver disease. All were former i.v. drug addicts, with a mean age of 32±4 years, and had clinical and histological evidence of chronic hepatitis (10% with cirrhosis). The CDC stage was A1 in five, A2 in 14, A3 in eight, B2 in eight, B3 in three and C3 in three. Twenty four patients were on triple therapy with protease inhibitors, 11 were on two-drug anti-HIV regimen…

AdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisSubstance-Related DisordersAlpha interferonHIV InfectionsHepacivirusChronic liver diseaseAntiviral AgentsGastroenterologyLiver diseaseInternal medicinemedicineHumansPharmacology (medical)Interferon alfabusiness.industryHIVInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseCD4 Lymphocyte CountTreatment OutcomeInfectious DiseasesImmunologyPatient ComplianceFemaleViral diseasebusinessViral loadmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

HIV-related non-Hodgkin lymphomas affecting the oral cavity: a clinicopathologic study of 11 cases

2021

HIV-related non-Hodgkin lymphomas of the oral cavity are rare lesions with aggressive clinical behaviour. The aim of this study is to describe the clinicopathological features of a series of HIV-related oral non-Hodgkin lymphomas. Eleven cases of oral lymphomas affecting HIV-positive patients were retrieved from 2012 to 2019. Clinicopathological features regarding age, sex, tumour location, clinical presentation, laboratory findings, disease stage and follow-up were obtained. Histologic, immunohistochemical and in situ hybridization for EBV detection were done for diagnosis confirmation. Overall survival was estimated by Kaplan?Meier curve. Males predominated, with a mean age of 40.3 years-…

AdultMaleMouthimpacted toothLymphoma Non-HodgkinHIV InfectionsOtorhinolaryngologypanoramic radiographydental cariesHumansSurgerythird molarLymphoma Large B-Cell Diffusedigital radiographyGeneral DentistryUNESCO:CIENCIAS MÉDICASIn Situ HybridizationMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Extremely High Mutation Rate of HIV-1 In Vivo.

2015

Rates of spontaneous mutation critically determine the genetic diversity and evolution of RNA viruses. Although these rates have been characterized in vitro and in cell culture models, they have seldom been determined in vivo for human viruses. Here, we use the intrapatient frequency of premature stop codons to quantify the HIV-1 genome-wide rate of spontaneous mutation in DNA sequences from peripheral blood mononuclear cells. This reveals an extremely high mutation rate of (4.1 ± 1.7) × 10−3 per base per cell, the highest reported for any biological entity. Sequencing of plasma-derived sequences yielded a mutation frequency 44 times lower, indicating that a large fraction of viral genomes …

AdultMaleMutation rateSequence analysisQH301-705.5Nonsense mutationHIV InfectionsBiologyGeneral Biochemistry Genetics and Molecular BiologyYoung AdultMutation RateHumansMutation frequencyBiology (General)GeneticsGeneral Immunology and MicrobiologySequence Analysis RNAGeneral NeuroscienceMiddle AgedVirologyReverse transcriptaseStop codon3. Good healthMutation (genetic algorithm)Disease ProgressionSynopsisHIV-1FemaleGeneral Agricultural and Biological SciencesViral loadResearch ArticlePLoS Biology
researchProduct

Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors

2005

BACKGROUND:The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants.OBJECTIVE:To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine.METHODS:Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels >1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL >20 copies/mL but <1000 copies/mL. Virolog…

AdultMaleNevirapineHIV InfectionsViremiaImmunopathologyDrug Resistance ViralHumansMedicinePharmacology (medical)Protease inhibitor (pharmacology)NevirapineProspective StudiesSidabiologyReverse-transcriptase inhibitorbusiness.industryHIV Protease InhibitorsMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseVirologyToxicityHIV-1FemaleViral diseasebusinessFollow-Up Studiesmedicine.drugAnnals of Pharmacotherapy
researchProduct

Prevalence of Occult Hepatitis B Virus Infection in a Cohort of HIV-Positive Patients Resident in Sicily, Italy

2013

Occult hepatitis B virus (OBI) in HIV-infected groups is still debated, as well as the associated risk-factors and clinical significance. In this paper, we examined a total of 405 HBsAg-negative/HIV-infected patients enrolled from January 2007 to December 2009. Overall, the prevalence of OBI was 5.9% (95% confidence interval (CI95%): 3.8–8.7%); it was more frequently associated with “anti-HBc alone” serological marker (11.3%; adjusted odds ratio = 3.7, CI95%: 1.4–9.8), although it was also detected in the absence of any HBV serological marker (4.9%; CI95%: 2.3–9.1%). A low prevalence of anti-HCV-positive patients with OBI was found (3.1%; CI95%: 0.6–8.7%). HIV RNA plasma levels or other imm…

AdultMaleOccult HBV HIV Prevalence Sicily Italymedicine.medical_specialtyHepatitis B virusArticle Subjectlcsh:MedicineHIV Infectionsmedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataGeneral Biochemistry Genetics and Molecular BiologySerologyInternal medicineGenotypemedicinePrevalenceHumansClinical significanceSicilyDemographyHepatitis B virusHepatitis B Surface AntigensGeneral Immunology and Microbiologybusiness.industrylcsh:Rvirus diseasesGeneral MedicineOdds ratioHepatitis Bmedicine.diseaseHepatitis BOccultdigestive system diseasesCohortImmunologyClinical StudyFemalebusiness
researchProduct